Adult primary hemophagocytic syndrome
Conditions
Interventions
Group A:Ruxolitinib+dexamethasone
Sponsors
the First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Meet the HLH-2004 diagnostic criteria; 2. Age>=18; 3. Women of childbearing age must be confirmed by a pregnancy test that they are not pregnant, and are willing to take effective contraceptive measures during the test period and within >= 12 months after the last dose; pregnant and lactating women cannot participate; Take contraceptive measures during the test period and within >=3 months after the last dose; 4. Can provide informed consent, can understand and comply with the requirements of the study.
Exclusion criteria
Exclusion criteria: 1. According to the New York Heart Association (NYHA) score, patients with heart disease of grade II or above (including grade II); 2. HIV-infected patients; 3. Patients with severe renal dysfunction (glomerular filtration rate 20); 5. Uncontrollable infections (including lung infections, intestinal infections, etc.); 6. Have serious mental illness; 7. Have a history of active tumor; 8. Participate in other clinical investigators at the same time; 9. People with central nervous system involvement; 10. Exclusion criteria related to concomitant medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival at 60 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate (ORR, CR, PR);Overall survival at 6 months;Time required to achieve remission;Duration of remission;Trend of related indicators;Security; | — |
Countries
China
Contacts
Public ContactYe Xiujin
The First Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed